Selling, General, and Administrative Costs: argenx SE vs Jazz Pharmaceuticals plc

SG&A Expenses: argenx SE's Rapid Growth vs Jazz's Stability

__timestampJazz Pharmaceuticals plcargenx SE
Wednesday, January 1, 20144061140004241601.57
Thursday, January 1, 20154491190005392385.38
Friday, January 1, 20165028920007370036.73
Sunday, January 1, 201754415600014970357
Monday, January 1, 201868353000031413266
Tuesday, January 1, 201973694200072279461
Wednesday, January 1, 2020854233000183907682
Friday, January 1, 20211451683000307644000
Saturday, January 1, 20221416967000472132000
Sunday, January 1, 20231343105000709539000
Loading chart...

Unlocking the unknown

A Tale of Two Biopharma Giants: SG&A Expenses Over Time

In the competitive world of biopharmaceuticals, managing operational costs is crucial for sustained growth. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry leaders: argenx SE and Jazz Pharmaceuticals plc, from 2014 to 2023.

Key Insights

Jazz Pharmaceuticals has consistently maintained higher SG&A expenses, peaking in 2021 with a 79% increase from 2014. This reflects their aggressive market expansion and robust operational strategies. In contrast, argenx SE, a rising star, showcased a staggering 16,600% increase in SG&A expenses over the same period, indicating rapid growth and scaling efforts.

Conclusion

While Jazz Pharmaceuticals' expenses highlight stability and maturity, argenx SE's exponential rise underscores its dynamic growth trajectory. Investors and stakeholders should consider these trends when evaluating the strategic directions of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025